159 related articles for article (PubMed ID: 22950608)
1. Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC
Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Demolis P; Moreau A; Hemmings RJ; O'Connor D; Brown D; Shepard T; Abadie E; Pignatti F
Oncologist; 2012; 17(4):543-9. PubMed ID: 22477727
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
5. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Pal SK; Twardowski P; Sartor O
Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
[TBL] [Abstract][Full Text] [Related]
6. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
8. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel: a novel microtubule inhibitor.
Villanueva C; Bazan F; Kim S; Demarchi M; Chaigneau L; Thiery-Vuillemin A; Nguyen T; Cals L; Dobi E; Pivot X
Drugs; 2011 Jul; 71(10):1251-8. PubMed ID: 21770474
[TBL] [Abstract][Full Text] [Related]
10. Tubulin-targeted agents including docetaxel and cabazitaxel.
Cheetham P; Petrylak DP
Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.
Ramaswamy B; Puhalla S
Drugs Today (Barc); 2006 Apr; 42(4):265-79. PubMed ID: 16703123
[TBL] [Abstract][Full Text] [Related]
12. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
Keating GM
Drugs Aging; 2013 May; 30(5):359-65. PubMed ID: 23532557
[TBL] [Abstract][Full Text] [Related]
14. New treatments for metastic prostate cancer.
Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
[TBL] [Abstract][Full Text] [Related]
15. Current chemotherapeutic approaches for androgen-independent prostate cancer.
Rumohr JA; Chang SS
Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
[TBL] [Abstract][Full Text] [Related]
16. Tubulin: an example of targeted chemotherapy.
Seligmann J; Twelves C
Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
[TBL] [Abstract][Full Text] [Related]
17. Epothilones in prostate cancer: review of clinical experience.
Dawson NA
Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Figg WD; Figg WD
Cancer Biol Ther; 2010 Dec; 10(12):1233-4. PubMed ID: 21107022
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for prostate cancer].
Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
[TBL] [Abstract][Full Text] [Related]
20. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
